ThermoGenesis Holdings, Inc. · OTC:THMO
ThermoGenesis — Cesca Therapeutics — Presentation to Dawson James Securities (May 2017)
22 slides from ThermoGenesis's conference presentation, May 11, 2017
Slide 1: Clinical Excellence in Stem Cell Applications
SK A Boyalife Company Clinical Excellefigiadn Stem Cell Applications Presentation to Dawson James Securities May 11, 2017 Chris Xu, Ph.D., Chairman & Interim CEO Vivian Liu, COO
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current views and assumpt
Slide 3: Who We Are
Who We Are > Cesca is a leading regenerative medicine company that develops, commercializes and markets automated technologies for cell-based therapeutics. = Device division — ThermoGenesis — develops and markets a full suite of solutions for automated clinical biobanking, point-of- care application
Slide 4: Financial Snapshot
nO 50 2050 20 50 28 22 22 28 oe oe oe oe 2 2 ee ee ees Financial Snapshot * Nasdaq: ¢ Recent close: ¢ Shares out: ¢ Fully diluted: ¢ Market cap: ¢ 52 Week High/Low: ¢ TTM Revenue: * Cash: ¢ Largest Shareholder: 4| NASDAQ: KOOL KOOL $3.23* 9.9 million 14.4 million $31.7 million $7.39/$1.85 $14 millio
Slide 5: Cell-Based Therapeutics — Next Pillar of Medicine?
Cell-Based Therapeutics — Next Pillar of Medicine? Cell-based therapeutics — next pillar of medicine M.A. Fischbach, JA. Bluestone and WA. Lim —— Science Translational Mediicine, Vol. 5, Issue 179, pp.179 Two decades ago, the pharmaceutical industry—long dominated by small-molecule drugs—was revolut
Slide 6: Cesca - Leading Provider of Automation for Cell-Based Therapeutics
Cesca - Leading Provider of Automation for Cell-Based Therapeutics &: ESCA Clinical Development (USA) A Boyalife Company [ ] , % eS thermogenesis’ Hecate Tou petent RC" (USA) Clinical Development (India) 6 | NASDAQ: KOOL
Slide 7: Global Clients in Stem Cell Industry
Global Clients in Stem Point-of-Care/Lab-based Cell Industry (partial list) cGMP 4New York Closed Systems Blood Center Scalable ° - cordlife ‘one chance, one choice TEXAS CRYOLIFE THE UNIVERSITY OF TEXAS HealthBaby MD Anderson 2 i hina CordBloed Corporation Ganeer Center 2 , Duke Or aemn mn mr ame r
Slide 8: Cesca's Automated Solutions for Cell-based Therapeutics
DSO N50 Ne 50 2 52 22 2 oe ee ee ne Se ne sees Cesca’s Automated Solutions for Cell-based Therapeutics * Clinical BioBanking AXP® + BioArchive® provide automated isolation, collection and storage of cord blood stem cell concentrates * Point-of-Care Solutions for Cell-Based Therapeutics MxXP™, allows
Slide 9: Strategic Focus
Strategic Focus (1) Advancing proprietary technologies for automated Point-of-Care (PoC) autologous cell processing 9| NASDAQ: KOOL
Slide 10: AutoXpress — Fast Growing Need for Autologous Cellular Processing at Point-of-Care
AutoXpress™ — Fast Growing Need for Autologous Cellular Processing at Point-of-Care Clinic Setting * MXP™ The AutoXpressTM Device delivers an automated, rapid, “smart- vision” based cell enrichment and ensures consistency and reliability at Point-of-Care setting Various applications for vascular dis
Slide 11: Point-of-Care for Autologous Cell Applications
Point-of-Care for Autologous Cell Applications rrowXpres: ¢ Fast Point-of-Care device for cellular processing in the Operating Room * Peripheral blood or bone marrow * Minimally manipulated * High cell dose accuracy and potency ° Safe and Fast + Autologous bone marrow derived stem cells * Single 60
Slide 12: Strategic Focus (II)
Strategic Focus (Il) (2) Developing clinical applications around proprietary Point-of-Care (PoC) platform 12| NASDAQ: KOOL
Slide 13: Strong Growth in Autologous Cell Applications
Strong Growth in Autologous Cell Applications —+ Autologous Related Donor Unrelated Donor g = a a 2 £ re '83 '84 '85 '86 '87 '88 '89 '90 '91 ‘92°93 '94'95'96 '97'98 99'00'01 02'03'04''05 '06 '07'08'09 10 Source: CIBMTR 13 | NASDAQ: KOC
Slide 14: Critical Limb Ischemia is the Most Severe Form of Peripheral Artery Disease
di 14 | NASDAQ: KOOL * Critical Limb Ischemia (CLI) is the Most Severe Form of Peripheral Artery Disease ~ 1M Incidences in the U.S. Fueled by the Epidemic of Diabetes and the Aging Population Results in “70,000 Major Amputations and 134,000 Minor Amputations per annum in the U.S. Dismal Patient Out
Slide 15: No Adverse Events Related to Treatment
No Adverse Events Related to Treatment Major Amputation-Free Rate Post- Therapy of 82.4% in “No-Option” Patient Cohort Verified Revascularization, with Improvements in: Collateral Vessel Numbers & Size Ankle Brachial Index (ABI) Transcutaneous Oxygen Pressure (TcPO2) Reduction in Pain Claudication P
Slide 16: US FDA Approved Phase III - CLI Clinical Trial
nO 50 2050 20 50 28 22 22 28 oe oe oe oe 2 2 ee ee ees US FDA Approved Phase III - CLI Clinical Trial Clinical Trial Design Endpoints Superiority Study — Treatment vs. Sham Primary Endpoint: + Randomized (1:1), Double Blinded Study + The difference in AFS measured over 12 + Rutherford 4&5 months bet
Slide 17: Pipeline in Development
Pipeline in Development AMI 40 Phase 1b IRB Approved Stroke 415 Phase 1a Under Regulatory Review Cardiovascular ay Phase 1b Completed (Intra- CLI 13 Muscular) Phase 1 Completed (Intra-Arterial) Non Healing Ulcers 10 Pilot OA 50 Pilot Completed A . 30 Pilot Completed Non U: Onineaaclte behest 17 Phas
Slide 18: Building a Pipeline Around Proprietary Platform
Building a Pipeline Around Proprietary Platform Indication Pre-Clinical/Pilot PI/ib Pu Pll Platform Market Vascular AMI Single Patient SurgWerks | $700M cu SurgWerks $28 Ischemic Stroke | éE Non-Healing Ulcer Eo $800M Orthopedic SIS Spinal Fusion surgWerks | $800M Osteoarthritis surgWerks | $5B Non-
Slide 19: Strategic Focus (III)
Strategic Focus (Ill) (3) Developing automations for immuno-oncology applications, i.e. CAR-T 19 | NASDAQ: KOOL
Slide 20: Immuno-Oncology Applications
Immuno-Oncology Applications CXP™ + BioArchive® = automated manufacturing, expansion and storage of cellular therapies for immuno-oncology, including various T-cell and nature killer (NK) cell based therapies 20 | NASDAQ: KOOL pes
Slide 21: Milestones for Next Months
Milestones for Next 12 Months ¢ Expand medical device product pipeline ¢ Transform clinical program by building a robust clinical pipeline based on proprietary AutoExpress™ platform ¢ Secure one or more strategic partnerships for clinical co-development fCESCA 21| NASDAQ: KOOL aN
Slide 22: Thank You!
Thank You ! Company Contact: Vivian Liu vliu@cescatherapeutics.com 916-858-5185 Investor Contact: Paula Schwartz Paula Schwartz <pschwartz@rxir.com> RX Communications 917-322-2216
Cesca Therapeutics — Presentation to Dawson James Securities (May 2017) on 6ix